{"DataElement":{"publicId":"11206806","version":"1","preferredName":"Vaccine Herpes Zoster Administered Type","preferredDefinition":"A description of the herpes zoster vaccine that was administered.","longName":"HZ_ VACCN_TYP","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"11483507","version":"1","preferredName":"Vaccine Herpes Zoster Administered","preferredDefinition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.:A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area._The act of having given something (e.g., a medication or test).","longName":"2398810v1.00:11483506v1.00","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2398810","version":"1","preferredName":"Vaccine","preferredDefinition":"Suspensions of killed or attentuated microorganisms (bacteria, viruses, or rickettsiae), or of antigenic proteins derived from them, administered for the prevention, amelioration, or treatment of infectious diseases or cancer.","longName":"C923","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF1C626B-A28D-1F9E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"HEGDES","dateCreated":"2005-08-29","modifiedBy":"ONEDATA","dateModified":"2005-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11483506","version":"1","preferredName":"Herpes Zoster Administered","preferredDefinition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area._The act of having given something (e.g., a medication or test).","longName":"C71079:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herpes Zoster","conceptCode":"C71079","definition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBDDC24D-ED19-6782-E053-731AD00A85DF","latestVersionIndicator":"Yes","beginDate":"2022-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-25","modifiedBy":"KUMMEROA","dateModified":"2022-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2831222","version":"1","preferredName":"Vaccine Therapy","preferredDefinition":"Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.","longName":"C15347","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6206C3D8-38E9-7329-E040-BB89AD436A24","latestVersionIndicator":"Yes","beginDate":"2009-02-03","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-03","modifiedBy":"CURTIST","dateModified":"2009-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EBDDC24D-ED1A-6782-E053-731AD00A85DF","latestVersionIndicator":"Yes","beginDate":"2022-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-25","modifiedBy":"KUMMEROA","dateModified":"2022-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11206803","version":"1","preferredName":"Herpes Zoster Vaccine Type","preferredDefinition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area._Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response._Something distinguishable as an identifiable class based on common qualities.","longName":"11206803v1.00","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Older version, Zostavax","valueDescription":null,"ValueMeaning":{"publicId":"11206804","version":"1","preferredName":"Old Version Varicella-Zoster Virus Strain Oka/Merck Live Antigen","longName":"11206804v1.00","preferredDefinition":"Not new, of an earlier time._A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._A sterile, lyophilized preparation of the Oka/Merck strain of the live, attenuated varicella-zoster virus (VZV), that can be used to prevent varicella, commonly known as chickenpox, or herpes zoster (HZ), commonly known as shingles. Upon reconstitution and subcutaneous vaccination with the VZV strain Oka/Merck live antigen, this vaccine induces antigen-specific T-cell and B-cell immune responses against the VZV, thereby protecting against VZV infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Old","conceptCode":"C65010","definition":"Not new, of an earlier time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Version","conceptCode":"C25714","definition":"A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Varicella-Zoster Virus Strain Oka/Merck Live Antigen","conceptCode":"C77799","definition":"A sterile, lyophilized preparation of the Oka/Merck strain of the live, attenuated varicella-zoster virus (VZV), that can be used to prevent varicella, commonly known as chickenpox, or herpes zoster (HZ), commonly known as shingles. Upon reconstitution and subcutaneous vaccination with the VZV strain Oka/Merck live antigen, this vaccine induces antigen-specific T-cell and B-cell immune responses against the VZV, thereby protecting against VZV infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E841DA46-AD0C-5719-E053-731AD00A6957","latestVersionIndicator":"Yes","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"MMADDINENI","dateModified":"2022-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E841DA46-AD0E-5719-E053-731AD00A6957","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"MMADDINENI","dateModified":"2022-09-09","deletedIndicator":"No"},{"value":"Newer version, Shingrix","valueDescription":null,"ValueMeaning":{"publicId":"11206805","version":"1","preferredName":"New Version Zoster Vaccine Recombinant, Adjuvanted","longName":"11206805v1.00","preferredDefinition":"Having no previous example or precedent or parallel; of a kind not seen before._A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Version","conceptCode":"C25714","definition":"A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Zoster Vaccine Recombinant, Adjuvanted","conceptCode":"C88288","definition":"A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E841DA46-AD0D-5719-E053-731AD00A6957","latestVersionIndicator":"Yes","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"MMADDINENI","dateModified":"2022-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E841DA46-AD0F-5719-E053-731AD00A6957","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"MMADDINENI","dateModified":"2022-09-09","deletedIndicator":"No"},{"value":"Don't know","valueDescription":null,"ValueMeaning":{"publicId":"3421449","version":"1","preferredName":"I don't know","longName":"3421449","preferredDefinition":"The answer is not known by the person answering.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Does Not Know","conceptCode":"C67142","definition":"The answer is not known by the person answering.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC29D17C-C0B7-627F-E040-BB89AD4304F7","latestVersionIndicator":"Yes","beginDate":"2012-03-26","endDate":null,"createdBy":"WOLFC","dateCreated":"2012-03-26","modifiedBy":"KUMMEROA","dateModified":"2022-05-05","changeDescription":"Added concept annotation and removed special characters for MDR data migration. 3.16.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E841DA46-AD10-5719-E053-731AD00A6957","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"MMADDINENI","dateModified":"2022-09-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"11257881","version":"1","preferredName":"Herpes Zoster Vaccine Type","preferredDefinition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area._Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response._Something distinguishable as an identifiable class based on common qualities.","longName":"11257881v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herpes Zoster","conceptCode":"C71079","definition":"A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vaccine","conceptCode":"C923","definition":"Preparations containing substances with antigenic properties administered to activate the immune system, thereby inducing an immune response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8D13394-AFA0-60AB-E053-731AD00AB4B0","latestVersionIndicator":"Yes","beginDate":"2022-09-16","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-16","modifiedBy":"MMADDINENI","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E841B90D-971C-53E6-E053-731AD00A1E22","latestVersionIndicator":"Yes","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"KUMMEROA","dateModified":"2022-10-25","changeDescription":null,"administrativeNotes":"2022.10.25 Reviewed and released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What type of herpes zoster vaccine was administered?","url":null,"context":"DCP"},{"name":"DCP Text 1","type":"Alternate Question Text","description":"If Yes, was it the older version, Zostavax, or newer version, Shingrix?","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E841EC71-BB73-598C-E053-731AD00A0503","latestVersionIndicator":"Yes","beginDate":"2022-09-09","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-09","modifiedBy":"KUMMEROA","dateModified":"2022-10-25","changeDescription":null,"administrativeNotes":"09/09/2022- Created CDE for DCP-INT21-05-01 SVAR- MM 2022.10.25 Replaced DEC 11206667 with new DEC 11483507. ak","unresolvedIssues":null,"deletedIndicator":"No"}}